Founded in 2008, Guangzhou Shijing Medical Software Co., Ltd. is a medical technology company dedicated to innovation and R&D in the fields of ophthalmology and optometry. The company focuses on the in-depth research of cutting-edge technologies such as artificial intelligence, image analysis, and virtual reality, with a commitment to becoming a leader in full-lifecycle functional eye disease solutions.
Main Products and Market Application
The company's main products include the digital diagnosis and treatment solution for visual function training — Duobaoshi, and the PBM photobiomodulation digital diagnosis and treatment solution — Beibeile. These products have been widely used in more than 3,000 ophthalmic hospitals and optometry centers across China, as well as in home treatment scenarios. With cumulative users exceeding 500,000, they have received unanimous praise from clinical doctors and patients' parents. Among similar products, the company's market share has consistently maintained an industry-leading position.
Continuous Innovation in Cutting-Edge Technology
The company has laid out more than 200 intellectual property rights, including over 60 authorized invention patents. Guangzhou Shijing Medical continues to invest in R&D and innovation in cutting-edge technologies such as artificial intelligence, image analysis, and virtual reality. It has successively obtained provincial-level key R&D project approvals and has carried out clinical trials and scientific research project cooperation with a number of well-known domestic medical institutions, making important contributions to promoting the development of ophthalmic medical care.
Industry Standards and Research Reports
Guangzhou Shijing Medical has led or participated in the formulation of multiple team standards and industry standards, such as the VR Visual Training System Technical and Application Specifications. It has also jointly released important industry research reports with Frost & Sullivan and MedSci, including the 2026 Blue Book on the Development Status and Future Trends of the Children and Adolescents Myopia Management Industry, the Blue Book on the Current Status of Digital Treatment for Children's Strabismus and Amblyopia in China, and the White Paper on the Current Status of Digital Treatment for Children's Strabismus and Amblyopia in China, promoting the steady development of the visual health industry.
Honors and Recognition
The company has successively been listed on the "Guangzhou Top 100 High-Tech Enterprises to be Listed" and selected for the "Deloitte China Rising Star" list. It has also been honored with recognitions such as "China's Top 10 Digital Therapeutics", the "Global Ophthalmology Clinical Application Award", and "China's Leading Brand in Visual Function Training".
Contact Information
-
Phone: +86 4008777511 / +86 15021168718
-
WeChat: yesmylord123
-
Email: fangtao@topeye.cn
-
Website: www.shijingmed.com
Conclusion
With a strong foundation in cutting-edge technology, a comprehensive product portfolio, and a clear commitment to innovation, Guangzhou Shijing Medical Software Co., Ltd. is well-positioned to lead the advancement of full-lifecycle functional eye disease solutions. Through continuous R&D investment, industry collaboration, and standard-setting, the company is not only enhancing its own competitiveness but also contributing to the broader goal of improving visual health for patients across China.
For more information, please visit: www.shijingmed.com
www.shijingmed.com
Guangzhou Shijing Medical Software Co., Ltd.,
